In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1835-1836

  Del Poeta, Maurizio ^a,b   Schell, Wiley A ^a   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; PNEUMOCANDIN DERIVATIVE;

ALTERNARIA; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; DILUTION; EXOPHIALA; HYPHOMYCETES; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PRIORITY JOURNAL;

EID: 0030854825     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1835     Document Type: Article

References (10)

1. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39: 314-319.
2. Fothergill, A. W., D. A. Sutton, and M. G. Rinaldi. 1996. Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi, abstr. F29, p. 105. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Najvar, L., A. Fothergill, M. Luther, and J. Graybill. 1996. Efficacy of L-743,872 (872) in murine disseminated candidiasis, abstr. F38, p. 106. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Najvar, L., J. Graybill, E. Montalbo, F. Barchiesi, and M. Luther. 1996. Evaluation of L-743,872 (872) in the treatment of murine histoplasmosis, abstr. F43, p. 107. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
5. National Committee for Clinical Laboratory Standards. 1995. Reference methods for broth dilution antifungal susceptibility testing for yeasts. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
6. Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1996. In vitro activity of L-743,872 against putatively amphotericin B (AmB) and fluconazole (Flu)-resistant Candida isolates, abstr. F28, p. 104. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Pujol, I., J. Guarro, C. Llop, L. Soler, and J. Fernández-Ballart. 1996. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob. Agents Chemother. 40:2106-2110.
8. Smith, J. G., G. K. Abruzzo, C. J. Gill, A. M. Flattery, L. Kong, H. Rosen, H. Kropp, and K. Bartizal. 1996. Evaluation of pneumocandin L-743,872 in neutropenic mouse models of disseminated candidiasis and aspergillosis, abstr. F41, p. 107. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Vazquez, J. A., D. Boikov, M. E. Lynch, and J. D. Sobel. 1996. In-vitro antifungal activity of L-743,872, a new pneumocandin, against sensitive and resistant Torulopsis and Candida species, abstr. F30, p. 105. In Abstracts of the 36th International Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Wheat, L. J. 1994. Fungal infections in the immunocompromised host, p. 211-237. In R. H. Rubin and L. S. Young (ed.), Clinical approach to infection in the compromised host, vol. 3. Plenum Publishing Corporation, New York, N.Y.